PDF herunterladen
Thromb Haemost 1986; 55(03): 410-414
DOI: 10.1055/s-0038-1661575
Original Article
Schattauer GmbH Stuttgart

A Comparison of the Antithrombotic and Haemorrhagic Effects of a Low Molecular Weight Heparin (LHN-1) and Conventional Heparin

V Diness
NOVO INDUSTRI A/S, Bagsvaerd, Denmark
,
J I Nielsen
NOVO INDUSTRI A/S, Bagsvaerd, Denmark
,
P C Pedersen
NOVO INDUSTRI A/S, Bagsvaerd, Denmark
,
K H Wolffbrandt
NOVO INDUSTRI A/S, Bagsvaerd, Denmark
,
P B Østergaard
NOVO INDUSTRI A/S, Bagsvaerd, Denmark
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 14. Januar 1986

Accepted 23. April 1986

Publikationsdatum:
18. Juli 2018 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints

Summary

The antithrombotic effects after intravenous administration of a low molecular weight heparin (LHN-1) and conventional heparin were compared in a rabbit model of experimental thrombosis, where thrombus formation was induced by a combination of endothelial damage and stasis. Both compounds were able to prevent thrombosis completely. However, LHN-1 was significantly less potent than conventional heparin, the ratio between doses with the same antithrombotic effect being 2.4:1 on a weight basis. Bleeding times after administration of LHN-1 and conventional heparin were determined by tail transsection in anaesthetized rats and by template bleeding in the ear of conscious pigs. Given intravenously at a dose ratio of 2.4:1 (w/w), LHN-1 affected APTT less than conventional heparin, whereas the effects on haemostasis were not significantly different. In conclusion, it was found that after intravenous administration LHN-1 prevented experimental thrombosis as effectively as conventional heparin. However, the correlation between antithrombotic and haemorrhagic effects of LHN-1 was the same as that of conventional heparin. The corresponding relation in man remains to be determined.

Keywords

LMW heparin - Venous thrombosis - Bleeding - Experimental Summary
 

  • References

  • 1 Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 1982; 25: 475-485
    CrossrefPubMedGoogle Scholar
  • 2 Thomas DP, Merton RE, Lewis WE, Barrowcliffe TW. Studies in man and experimental animals of a low molecular weight heparin fraction. Thromb Haemostas 1981; 45: 214-218
    PubMedGoogle Scholar
  • 3 Bergqvist D, Hedner U, Sjorin E, Holmer E. Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously. Thromb Res 1983; 32: 381-391
    CrossrefPubMedGoogle Scholar
  • 4 Ockelford PA, Carter CJ, Mitchell L, Hirsh J. Discordance between the anti-Xa activity and the antithrombotic activity of an ultra-low molecular weight heparin fraction. Thromb Res 1982; 28: 401-409
    CrossrefPubMedGoogle Scholar
  • 5 Thomas DP, Merton RE, Barrowcliffe TW, Thunberg L, Lindahl U. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis. Thromb Haemostas 1982; 47: 244-248
    PubMedGoogle Scholar
  • 6 Buchanan MR, Boneu B, Ofosu F, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985; 65: 198-201
    PubMedGoogle Scholar
  • 7 Cade JF, Buchanan MR, Boneu B, Ockelford P, Carter CJ, Cerskus AL, Hirsh J. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation. Thromb Res 1984; 35: 613-625
    CrossrefPubMedGoogle Scholar
  • 8 Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-1245
    PubMedGoogle Scholar
  • 9 Bergqvist D, Nilsson B, Hedner U, Pedersen PC, Østergaard PB. The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis. Thromb Res 1985; 38: 589-601
    CrossrefPubMedGoogle Scholar
  • 10 Finney DJ. Statistical methods in biological assay. 3rd Edition Charles Griffin & Co. Ltd; London: 1978
    Google Scholar
  • 11 Teien AN, Lie M, Abildgaard U. Assay of heparins in plasma using a chromogenic substrate. Thromb Res 1976; 8: 413-416
    CrossrefPubMedGoogle Scholar
  • 12 Marquardt DL. An algorithm for least squares estimation of nonlinear parameters. J Soc Ind Appl Math 1963; 2: 181-190
    PubMedGoogle Scholar
  • 13 Andersson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Soderstrom G. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 1979; 15: 531-541
    PubMedGoogle Scholar
  • 14 Barrowcliffe TW, Curtis AD, Tomlinson TP, Hubbard AR, Johnson EA, Thomas DP. Standardization of low molecular weight heparins: A collaborative study. Thromb Haemostas 1985; 54: 675-679
    PubMedGoogle Scholar
  • 15 Handeland GF, Abildgaard U. Assay of unfractionated and LMW heparin with chromogenic substrates: Twin methods with factor Xa and thrombin. Thromb Res 1984; 35: 627-636
    CrossrefPubMedGoogle Scholar
  • 16 Denton J, Lane DA, Thunberg L, Slater AM, Lindahl U. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J 1983; 209: 455-460
    CrossrefPubMedGoogle Scholar
  • 17 Aiach M, Dreyfus G, Michaud A, Relland J, Murawski M, Leclerc M, Carpentier A. Low molecular weight (LMW) heparin derivatives in experimental extra-corporeal circulation (ECC). Haemostasis 1984; 14: 325-332
    PubMedGoogle Scholar
  • 18 Fareed J, Kumar A, Walenga JM, Emanuele RM, Williamson K, Hoppensteadt D. Antithrombotic actions and pharmacokinetics of heparin fractions and fragments. Nouv Rev Fr Hematol 1984; 26: 267-275
    PubMedGoogle Scholar
  • 19 Reyers I, Mussoni L, Donati MB, de Gaetano G. Failure of aspirin at different doses to modify experimental thrombosis in rats. Thromb Res 1980; 18: 669-674
    CrossrefPubMedGoogle Scholar
  • 20 DeClarck F, Goossens J, Reneman R. Effects of anti-inflammatory, anticoagulant and vasoactive compounds on tail bleeding time, whole blood coagulation time and platelet retention by glass beads in rats. Thromb Res 1976; 8: 179-193
    PubMedGoogle Scholar
  • 21 Heiden D, Mielke CH, Rodvien R. Impairment by heparin of primary haemostasis and platelets [14C]5-hydroxytryptamine release. Br J Haematol 1977; 36: 427-436
    CrossrefPubMedGoogle Scholar
  • 22 Holmer E, Lindahl U, Backstrom G, Thunberg L, Sandberg H, Soderstrom G, Andersson LO. Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. Thromb Res 1980; 18: 861-869
    CrossrefPubMedGoogle Scholar
  • 23 Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73
    CrossrefPubMedGoogle Scholar
  • 24 Mielke CH. Aspirin prolongation of the template bleeding time: Influence of venostasis and direction of incision. Blood 1982; 60: 1139-1142
    PubMedGoogle Scholar
  • 25 Stefaniszyn HJ, Novick RJ, Salerno TA. Toward a better understanding of the hemodynamic effects of protamine and heparin interaction. J Thorac Cardiovasc Surg 1984; 87: 678-686
    PubMedGoogle Scholar
  • 26 Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G. A double-blind multicenter trial comparing low molecular weight heparin once daily with low dose heparin twice daily: Thromboprophylactic effect and haemorrhagic complications. Thromb Haemostas 1985; 54: 234 (Abstr)
    PubMedGoogle Scholar
  • 27 Kakkar VV, Murray W JG. Efficacy and safety of a low-molecular-weight heparin (CY 216) in preventing postoperative venous thromboembolism: A cooperative study. Br J Surg 1985; 72: 786-791
    CrossrefPubMedGoogle Scholar